HOME >> BIOLOGY >> NEWS
Carnegie Mellon scientists find key HIV protein makes cell membranes bend more easily

PITTSBURGH -- Carnegie Mellon University scientists have made an important discovery that aids the understanding of why HIV enters immune cells with ease. The researchers found that after HIV docks onto a host cell, it dramatically lowers the energy required for a cell membrane to bend, making it easier for the virus to infect immune cells. The finding, in press in Biophysical Journal, will provide vital data to conduct future computer simulations of HIV dynamics to help further drug discovery and prevent deadly infections.

We found that HIV fusion peptide dramatically decreases the amount of energy needed to bend a cell-like membrane, said Stephanie Tristram-Nagle, associate research professor of biological physics at Carnegie Mellon. This helps membranes to curve, a necessary step for HIV to fuse with an immune cell as it infects it.

The Carnegie Mellon scientists used X-rays to study how HIV fusion peptide (part of a larger protein) affected the energy of manufactured lipid bilayers made to mimic normal cell membranes. Lipid bilayers provide a protective barrier for the cell against intruders, yet also contain molecules to recognize and communicate with other cells or get nutrients. Cells also communicate with one another via small, membrane-bound vesicles that contain proteins or other molecular cargo. When delivering their goods, vesicles from one cell fuse with the outermost membrane of another cell to form a series of hybrid structures called fusion intermediates.

Through evolution, viruses have also become skilled at fusing with cells to unload their genetic contents, which turn host cells into virus-producing factories. In the case of HIV, a molecule called gp120 initially helps the virus lock onto its host T cell, a cell critical for maintaining immunity. Another protein gp41 then enables HIV to penetrate a T-cell membrane. Fusion takes place specifically through a short stretch of gp41 called fusion peptide 23, or FP-23 for short
'"/>

Contact: Lauren Ward
wardle@andrew.cmu.edu
412-268-7761
Carnegie Mellon University
25-Jul-2007


Page: 1 2 3

Related biology news :

1. Carnegie Mellons Peter Adams receives EPA research grant
2. Carnegie Mellons David Sholl identifies new materials
3. Carnegie Mellon University scientists identify genes activated during learning and memory
4. Carnegie Mellon University research shows how sensory-deprived brain compensates
5. Carnegie Mellon researchers urge regulators to rethink strategies for soot emission
6. Carnegie Mellon researcher proposes development of artificial cells to fight disease
7. Carnegie Mellon engineers devise new process to improve energy efficiency of ethanol production
8. DNA gets new twist: Carnegie Mellon scientists develop unique DNA nanotags
9. Carnegie Mellons Granger Morgan pens op-ed
10. Carnegie Mellon scientist plays key role in unveiling sea urchin genome
11. Carnegie Mellon study reveals that odor discrimination is linked to the timing at which neurons fire

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/2/2020)... ... July 02, 2020 , ... ... detailing the use of its revolutionary NEXTGENPCR endpoint thermocycler to test for ... minutes. The article, titled "Ultra-fast one-step RT-PCR protocol for the detection of ...
(Date:6/28/2020)... ... June 25, 2020 , ... In an upcoming episode scheduled for the ... of Care Testing solutions (POCT). Check local listings for more info. , Today, the ... and are shipped to labs throughout the country. Results are then available several days ...
(Date:6/23/2020)... (PRWEB) , ... June 22, 2020 , ... The field ... Typically, ligand binding assays (LBA) have dominated this area. However, the use of mass ... years. , This now necessitates the question “How do you choose which approach to ...
Breaking Biology News(10 mins):
(Date:6/23/2020)... Ore. (PRWEB) , ... June 23, 2020 , ... ... of innovative CNS therapies, today announced that it has filed an Investigational New ... a Phase 2b clinical trial of its lead drug candidate NBTX-001 in patients ...
(Date:6/11/2020)... ... 09, 2020 , ... TRX Systems, developer of NEON® Indoor ... a highly accurate, contact tracing solution for identification of employees who may have ... disease control measure, is a key strategy for preventing further spread of COVID-19. ...
(Date:5/30/2020)... ... 2020 , ... Medrio, Inc., the leading provider of eClinical ... Cytovale, Inc., a medical technology company dedicated to revolutionizing diagnostics for conditions like ... in (FPI) in just seven days. The Cytovale technology will allow patients with ...
(Date:5/26/2020)... ... ... Brilliant , the leading smart home control and lighting company, and ... new integration to bring more convenience, simplicity, and security to the smart home industry. ... now be controlled from Brilliant’s in-wall touchscreen control panels and mobile app. , ...
Breaking Biology Technology:
Cached News: